A Double-blind [Sponsor Unblinded], Randomized, Placebo-controlled, Staggered-parallel Study to Investigate the Safety, Tolerability, and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs GSK 2890457 (Primary) ; Liraglutide; Metformin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Aug 2013 Planned end date changed from 1 Nov 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.